Bayer Aktiengesellschaft

Oki Electric Industry Co., Ltd.

Axikin Pharmaceuticals, Inc.

Bayer Pharma Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Bayer Pharmaceuticals Corporation

Toshiki Murata

Kinji Fuchikami

Takuya Shintani

Timothy B Lowinger

Takashi Yoshino

Mitsuyuki Shimada

Yuji Koriyama

Tsutomu Masuda

Kevin Bacon

Karl Ziegelbauer

Hiroki Sato

Hiroshi Komura

Masaomi Umeda

Sachiko Sakakibara

Klaus Urbahns

Hiroshi Kadono

Keiko Fukushima

Noriko Nunami

Sayori Shimohata

Mihoko Kitamura

Megumi Yamauchi

Toshiya Moriwaki

Yingfu Li

Timothy Lowinger

Hiroko Yoshino

Norihiro Kawamura

Mitsuiyuki Shimada

Takashi Yoshiro

Florian Gantner

Mami Miura

Issei Kato

Naoki Omori

Tetsuo Kikuchi

Akihiko Watanabe

Rolf Grosser

Atsushi Ikeno

Hideki Yamamoto

Nagahiro Yoshida

Masachika Fuchigami

Tatsuya Sukehiro

Sachiko Sasaki

Tsuyoshi Fukui

Miki Sasaki

Ikuo Orihara

Makoto Shimazaki

Yuka Ikegami

Hideki Tsujishita

Shigehiro Kato

Miho Tanaka

Hideki Jishita

Yoshino Hiroko

A dialogue control system that uses an ontology that systematically expresses domain knowledge representing concepts and relationships between concepts to determine questions for a user and implements the questions, and implements a dialogue in accordance with received user answers. One or more dimension-classified ontologies and a basic ontology are stored, a concept from a user response is specified as a condition, and one or a plural number of the dimension-classified ontologies that meet the specified condition are fetched. The content of the fetched dimension-classified ontology/ies is overwritten on the basic ontology, in order according to dimension priorities from the dimension-classified ontology with the lowest dimension priority, and a multidimensional ontology is generated. The dialogue control system uses this multidimensional ontology to control the dialogue.

Dialogue control system, method and computer readable storage medium, and multidimensional ontology processing system, method and computer readable storage medium

The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders.

Arylsulfonamide derivatives for use as CCR3 antagonists in the treatment of inflammatory and immunological disorders

The present invention relates to novel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-&#x3b3; inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-&#x3b3; activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoimmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.

Fused azole-pyrimidine derivatives

Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders

The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-&#x3b3; inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-&#x3b3; activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.

Pyrimidine compounds of general formula: wherein &#x2014;Rrepresents in which Ris hydrogen, Calkyl, halogen, hydroxy, Calkoxy, nitro, amino, Calkylsulfonylamino, Calkoxycarbonyl, Calkylamino, di (Calkyl)amino, Calkanoylamino, phenyl Calkylamino, phenylsulfonylamino, or &#x2014;O&#x2014;(CH)&#x2014;R; Rrepresents hydrogen or halogen; Rrepresents hydrogen, &#x2014;CRRR; Ris hydrogen, carbamoyl, CN, carboxyl, etc.; Ris amino, Calkylamino, di Calkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.

Pyridine derivatives

4-aryl pyrimidine compounds of general formula and salts thereof: wherein X is CH or N; R1 is hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, etc.; R2 is hydrogen or hydroxy; R3 is hydrogen, C1-6 alkyl, etc.; R4 is hydrogen, hydroxy, halogen, amino, etc.; R5 is hydroxy, amino, carboxy, etc.; R6 is hydrogen, carbamoyl, cyano, carboxy, C1-6 alkoxycarbonyl, etc. and R7 is amino or C1-6 alkanoylamino. The compounds (I) or the salts thereof have an excellent anti-inflammatory activity and the like.

4-6-diphenyl pyridine derivatives as antiinflammatory agents

An optically active (&#x2212;)-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one of the formula (I) or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity 

Optically active pyridine derivative and a medicament containing the same

This invention is to provide a process for producing 2-amino-4,6-disubstituted nicotinic acid ester analogs and salts thereof, comprising the reaction shown by the following scheme. The ester analogs can be prepared in one pot, and in good yield by using tertiary alkyl cyanoacetate. Furthermore, the method is useful for preparing derivatives of various analogs of the ester, e.g. alkyl substituted and aryl substituted analogs. 

A conversation system according to the invention includes: a network; a server apparatus which transfers a conversation based on characters through the network; plural terminal apparatuses which perform the conversation based on the characters under the transfer by the server apparatus through the network; and a translating apparatus which is connected to the network, receives a conversation that is transmitted from one of the plural terminal apparatuses through the network and based on characters of one language, translates the received conversation based on the characters of one language into a conversation based on characters of another language, and transmits the translated conversation based on the characters of another language to the server apparatus. The server apparatus transfers the conversation that is received from the translating apparatus and based on the characters of another language to at least one terminal apparatus during a conversation among the plural terminal apparatuses.

System and method for character-based conversation through a network between different languages

The present invention provides an apparatus and method for natural language processing capable of providing an appropriate result of natural language processing. More specifically, the present invention provides a natural language processing apparatus for achieving a syntax analysis and/or a syntax generation by using natural language patterns with, at least, pattern name and pattern component. The natural language processing apparatus comprises dictionary reference means for picking up one or more natural language patterns applicable for the syntax analysis and/or the syntax generation among the natural language patterns prepared in a pattern dictionary in advance, pattern inspection means for inspecting whether the applicable natural language patterns meet a tree structure or not, and pattern application means for applying the natural language patterns to the tree structure if the natural language patterns meet the tree structure.

Apparatus and method for natural language processing

Pyridine compounds of general formula:wherein &#x2014;Rrepresentsin which Ris hydrogen, Calkyl, halogen, hydroxy, Calkoxy, nitro, amino, Calkylsulfonylamino, Calkoxycarbonyl, Calkylamino, di (Calkyl)amino, Calkanoylamino, phenyl Calkylamino, phenylsulfonylamino, or &#x2014;O&#x2014;(CH)&#x2014;R; Rrepresents hydrogen or halogen; Rrepresents 1.2.3.6-tetrahydro-pyridine, or &#x2014;CRRRwherein Rrepresents H or Calkyl and Rand Rare joined to form a 5-8 membered saturated ring optionally containing up to three heteroatoms; Ris carbamoyl, CN, carboxyl, etc.; Ris amino, Calkylamino, di Calkylamino, etc. or salt thereof. The compound has an excellent anti-inflammatory activity, and other biological activity.

Given a source text, a desired translation of the source text into a target language, and a machine-readable dictionary, a first set of morphemes in the target language is generated from the source text, typically by using the dictionary to perform a machine translation of the source text. The second text is analyzed into a second set of morphemes in the target language. Differences between the first and second sets of morphemes are found, and morphemes corresponding to the differences are taken from the source text. Existing information including these source-text morphemes is extracted from the dictionary, and new information to be added to the dictionary is automatically generated from the extracted information and the differences. This process generates comparatively short dictionary entries, corresponding only to the differences between the two set of morphemes, and therefore creates useful dictionary entries while saving dictionary space.

Apparatus and method for adding information to a machine translation dictionary

A document retrieval and display system for retrieving source documents in different languages from servers linked by a communication network, translating the retrieved source documents as necessary, storing the translated documents, and displaying the source documents and translated documents at a client device connected to the communication network. The translation process is activated automatically by a control module, and is carried out by a machine translation module. The control module decides when a translation is necessary, selects whether to display the source document or a translated document at the client device, and determines when the source document has been updated and must be retranslated.

System and method for efficiently retrieving and translating source

Growing community of inventors

Nara, Japan

Toshiki Murata